Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 5, 2025Thoracic CancerOpen Access

A Real‐World Study of Resectable NSCLC Following Neoadjuvant Immunotherapy: Should Postoperative Adjuvant Immunotherapy be Recommended?

View Full Paper
Ask AI
Bookmark
Share

Authors

MLMing LiHYHao YinYJYue Jin

Discussion

Loading...

Member takes

Implication

Retrospective cohort analysis shows adjuvant immune checkpoint inhibitors improve event-free survival in NSCLC patients with incomplete pathological responses, suggesting personalized treatment is key

Key Points

  • Postoperative adjuvant immune checkpoint inhibitor therapy improves event-free survival in resectable NSCLC patients without major pathological response.
  • Among 186 patients, those without major pathological response showed significant improvement in event-free survival with adjuvant therapy (p = 0.004).
  • Retrospective cohort study assessed survival outcomes in resectable NSCLC patients treated with neoadjuvant immunotherapy and adjuvant therapies.
  • Findings suggest personalized approach is needed for optimal use of postoperative therapies in NSCLC.

Cite This Study

Li et al. (2025) studied this question.

synapsesocial.com/papers/693231368e51979591dceca3https://doi.org/10.1111/1759-7714.70195
View Full Paper
Ask AI
Bookmark
Share